MYSZ
My Size, Inc.
There isn't enough reported data to score MYSZ yet.
NVDA
NVIDIA Corporation
NVDA's fundamentals are strong and it looks cheap: trading at 21x earnings, about a third of its usual 65x. Analysts expect strong earnings growth.
MYSZ Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
MYSZ's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
MYSZ PE Valuation
MYSZ has no meaningful PE right now: it lost money over the past year.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 12x next year's earnings.
MYSZ Forward outlook
There aren't enough analyst estimates for MYSZ to show an outlook.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
MYSZ Earnings Per Share
MYSZ and NVDA do not have enough comparable growth data to identify a winner.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA's earnings per share have climbed steadily: $7.91 over the past year, up 125% from the year before, and higher year over year for 13 quarters in a row.
MYSZ Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $3.1M | +53% |
| Q1 2026 | $2.4M | +62% |
| Q4 2025 | $3.3M | +127% |
| Q3 2025 | $2.6M | +40% |
| Q2 2025 | $2M | +1.4% |
| Q1 2025 | $1.5M | -50% |
| Q4 2024 | $1.5M | -49% |
| Q3 2024 | $1.8M | -15% |
MYSZ's revenue has grown year over year for five quarters in a row: $3M last quarter, up 53% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -56% | -27 points |
| Q1 2026 | -59% | +13 points |
| Q4 2025 | -83% | -35 points |
| Q3 2025 | -53% | +18 points |
| Q2 2025 | -29% | +15 points |
| Q1 2025 | -72% | -36 points |
| Q4 2024 | -47% | +8.8 points |
| Q3 2024 | -71% | -20 points |
MYSZ's operating margin was −56% last quarter, down 27 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over MYSZ on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over MYSZ on profitability, with a higher operating margin.
MYSZ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$2.1M | -$847K |
| Q3 2025 | -$500K | -$53K |
| Q1 2025 | -$1.3M | +$149K |
| Q4 2022 | -$1.4M | +$1.9M |
| Q3 2022 | -$1.8M | -$475K |
| Q2 2022 | -$1.5M | -$88K |
| Q1 2022 | -$2.6M | -$1.3M |
| Q4 2021 | -$3.3M | -$1.4M |
NVDA has the stronger cash trend. Its trailing FCF is up 290% versus its history, compared with MYSZ at up 18%.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA's free cash flow has been positive every quarter for six years: $127B over the past year, up 76% from the year before.
MYSZ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +1.7K shares |
| 1 year | +129% | +339K shares |
| 3 years | +3674% | +585K shares |
| 5 years | +48138% | +599K shares |
MYSZ has 600,560 diluted shares, up 129% from a year ago.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has the edge over MYSZ on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
MYSZ Net Leverage
MYSZ's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
MYSZ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 21.2 | Oversold |
| Stochastic | 1.7 | Oversold |
MYSZ's weekly RSI is 21 (oversold) and its Stochastic is 2 (oversold).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
MYSZ PE vs Technology Sector
MYSZ has no meaningful PE right now: it lost money over the past year.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
MYSZ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.16 | 40% below |
| 20 week MA | $2.17 | 68% below |
| 50 week MA | $4.01 | 83% below |
| 100 week MA | $8.37 | 92% below |
| 200 week MA | $29.8 | 98% below |
MYSZ is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has the edge over MYSZ on trend strength, trading above more of its moving averages.
MYSZ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5,376.0 | $2,000.0 | -63% |
| 2021 | $2,000.0 | $1,036.8 | -48% |
| 2022 | $1,036.8 | $167.0 | -84% |
| 2023 | $167.0 | $43.2 | -74% |
| 2024 | $43.2 | $52.1 | +21% |
| 2025 | $52.1 | $6.58 | -87% |
| 2026 YTD | $6.58 | $0.70 | -89% |
MYSZ has finished lower in five of the last six years. It's down 89% so far in 2026.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA has the edge over MYSZ on returns for 2026, with the stronger performance.